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RhoA protects the mouse heart against
ischemia/reperfusion injury
Sunny Yang Xiang,1 Davy Vanhoutte,2 Dominic P. Del Re,1,3 Nicole H. Purcell,1 Haiyun Ling,1
Indroneal Banerjee,4 Julie Bossuyt,5 Richard A. Lang,6 Yi Zheng,7 Scot J. Matkovich,8
Shigeki Miyamoto,1 Jeffery D. Molkentin,2 Gerald W. Dorn II,8 and Joan Heller Brown1
1Department

of Pharmacology, UCSD, San Diego, California, USA. 2Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center,
Cincinnati, Ohio, USA. 3Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School,
Newark, New Jersey, USA. 4Department of Medicine, UCSD, San Diego, California, USA. 5Department of Pharmacology, UCD, Davis, California, USA.
6Visual Systems Group, and 7Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center,
Cincinnati, Ohio, USA. 8Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.

The small GTPase RhoA serves as a nodal point for signaling through hormones and mechanical stretch. However, the role of RhoA signaling in cardiac pathophysiology is poorly understood. To address this issue, we
generated mice with cardiomyocyte-specific conditional expression of low levels of activated RhoA (CA-RhoA
mice) and demonstrated that they exhibited no overt cardiomyopathy. When challenged by in vivo or ex vivo
ischemia/reperfusion (I/R), however, the CA-RhoA mice exhibited strikingly increased tolerance to injury,
which was manifest as reduced myocardial lactate dehydrogenase (LDH) release and infarct size and improved
contractile function. PKD was robustly activated in CA-RhoA hearts. The cardioprotection afforded by RhoA
was reversed by PKD inhibition. The hypothesis that activated RhoA and PKD serve protective physiological
functions during I/R was supported by several lines of evidence. In WT mice, both RhoA and PKD were rapidly
activated during I/R, and blocking PKD augmented I/R injury. In addition, cardiac-specific RhoA-knockout
mice showed reduced PKD activation after I/R and strikingly decreased tolerance to I/R injury, as shown by
increased infarct size and LDH release. Collectively, our findings provide strong support for the concept that
RhoA signaling in adult cardiomyocytes promotes survival. They also reveal unexpected roles for PKD as a
downstream mediator of RhoA and in cardioprotection against I/R.
Introduction
RhoA is the best-characterized Rho family small GTPase, acting
as an intracellular signal transducer that modulates a range of cellular processes including adhesion, migration, invasion, cell cycle
progression, and gene expression (1–4). In light of the multiple
upstream regulators and downstream mediators of RhoA signaling, it is perhaps not surprising that its role in cardiac physiology
and pathophysiology remains elusive (5). On the one hand, there
are published data demonstrating that high levels of RhoA expression in cardiomyocytes can induce apoptosis (6) and cardiomyopathy (7, 8) and that the well-characterized RhoA effector Rho kinase
(ROCK) has deleterious effects on the heart (9–12). On the other
hand, expression of RhoA at a more physiological level can protect
cardiomyocytes against apoptosis induced by H2O2 or glucose deprivation (13) and inhibiting Rho leads to caspase-3 activation and
apoptosis (14). RhoA has also been implicated in adenosine-induced
cardioprotection against ischemia (15). To control for the myriad
contextual events that could influence the functional response to
RhoA, e.g., the cellular site and developmental stage of RhoA expression and the mechanism and extent of RhoA activation, we utilized
the attenuated α myosin heavy chain–driven (αMHC-driven) tetracycline-responsive (tet-off) system to generate transgenic mice with
conditional in vivo postnatal expression of modest levels of constitutively activated RhoA in cardiomyocytes. We demonstrate here
that when RhoA expression is induced in adult cardiomyocytes, neither hypertrophy nor cardiomyopathy ensues. Instead, the increase
in activated RhoA in cardiomyocytes confers remarkable protection
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against ischemia/reperfusion (I/R) injury in vivo and in the isolated
perfused heart. Conversely, cardiac-specific RhoA-knockout mice
are substantially more susceptible to I/R injury. We provide further
evidence suggesting that PKD, an enzyme not heretofore implicated
in cardiomyocyte survival, is a mediator of RhoA signaling and cardioprotection against I/R injury.
Results
Conditional cardiac-specific RhoA transgenic mice show no overt pathological phenotype. Conditional cardiomyocyte-specific expression of
constitutively activated (Q63L) RhoA (CA-RhoA) was achieved by
crossing transgenic mice expressing the RhoA transgene under
the control of an attenuated tetracycline-responsive αMHC promoter, with a mouse line expressing the tetracycline transactivator (tTA). Double-transgenic mice should express the regulated
transgene in cardiomyocytes shortly after birth in the absence of
tetracycline but not if animals are maintained on tetracycline (16).
Doxycycline (Dox), a stable analog of tetracycline, was administered to the breeding dams and pups throughout embryonic
development and until weaning (3 weeks of age). Two CA-RhoA
lines (line 7 and line 25), which showed respectively, 2- and 5-fold
increases in active RhoA in the LV at 8 weeks after Dox removal (off Dox) (Figure 1A) were extensively characterized. Cardiac
structure, dimension, and functional performance were normal
in both lines examined at 8 weeks and followed for 8 months off
Dox (Figure 1B and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI44371DS1).
Histological analyses revealed no overt pathology, hypertrophy, or
fibrosis in hearts from either line, as assessed by H&E and Masson’s trichrome (Tri) staining (Figure 1C). Thus, expression of
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Figure 1
Characterization of conditional cardiac-specific RhoA transgenic mice. (A) Top panel: time
line of Dox administration and sacrifice of animals for analysis. Bottom panel: activation and
expression of endogenous (WT) and transgenic (HA-tagged) RhoA in the LV of CA-RhoA
mouse hearts from lines 7 and 25 at various
times after Dox removal (off Dox). (B) Representative image of hearts from tTA and CA-RhoA
(line 25) mice (top panel). Scale bar: 5 mm.
Heart weight (HW) to body weight (BW) ratio
and heart weight to tibial length (TL) ratio from
WT, tTA, and CA-RhoA mice at 8 weeks or
8 months after Dox removal. Data are shown
as mean ± SEM. (C) Representative staining
of histological sections in tTA and CA-RhoA
(line 25) hearts by H&E staining (top). Scale
bars: 2 mm. Tri staining (middle) and TRITCconjugated, WGA staining of cell membranes
(bottom). Scale bars: 50 μm.

modest levels of RhoA in the adult mouse heart is not sufficient
to induce hypertrophy nor is it inherently pathological.
Notably, in some initial control experiments, breeding dams and
pups were not administered Dox, enabling RhoA expression during the early postnatal period. Three CA-RhoA lines (lines 7, 10,
and 25), which showed 3- to 7-fold increases in active RhoA, all
developed hypertrophy as assessed by heart weight to tibial length
ratio (Supplemental Figure 1). Comparison with the conditional
expression paradigm used in Figure 1 suggests that induction of
hypertrophy in response to activated RhoA reflects signaling events
that occur during heart development but not in adulthood.
CA-RhoA mice show increased tolerance against I/R injury in vivo and
in the isolated perfused heart. Our previous work demonstrated that
RhoA expression in cardiomyocytes can confer protection against
oxidative stress (13). To determine whether this occurs in vivo, we
examined the response to I/R injury in CA-RhoA mice. Control (WT,
tTA) and CA-RhoA (line 25) mice (8 weeks off Dox) were subject to
experimental myocardial I/R through ligation of the left anterior
descending artery (LAD) for 1 hour, followed by removal of the ligation and reperfusion for 24 hour. The area at risk (AAR) was not different in CA-RhoA versus control littermates (Figure 2A). Strikingly,
however, infarct size was 70% smaller in the CA-RhoA compared
with the control hearts (10% ± 1% vs. 37% ± 3% of AAR) (Figure 2B),
demonstrating in vivo protection against I/R injury.
To exclude a role for endogenous systemic neurohormonal mechanisms in the cardioprotection seen in CA-RhoA mice, further studies
were performed on isolated perfused hearts. Following a 30-minute
3270
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period of global ischemia, LV-developed pressure (LVDP) recovered over 45 minutes of reperfusion to 64% of preischemic values
in the CA-RhoA compared with only 25% in the controls. Postischemic maximum rate of contraction (+dP/dt) and maximum rate of
relaxation (–dP/dt) also showed more rapid and complete recovery
in CA-RhoA hearts than in control hearts (Figure 3A). To directly
assess myocardial cell damage, we examined lactate dehydrogenase
(LDH) accumulation in the coronary effluent during a 45-minute

Figure 2
RhoA activation protects against I/R injury in vivo. WT, tTA, and CA-RhoA
mice (8 weeks off Dox) were subjected to in vivo I/R. (A) Quantitative analyses of AAR as a percentage of ventricular area and (B)
infarct size as a percentage of AAR of hearts subjected to in vivo I/R.
*P < 0.001 versus WT/tTA (n = 5). Data are shown as mean ± SEM.
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Figure 3
RhoA activation protects against I/R injury in the isolated perfused heart. WT, tTA, and CA-RhoA mice (8 weeks off Dox) were subjected to
global I/R. (A) Time course recovery of contractility following ischemia measured by LVDP, +dP/dt, and –dP/d. *P < 0.001 versus WT/tTA (n = 7).
(B) LDH release to the coronary effluent following 45 minutes reperfusion. WT and tTA were not significantly different, and data were pooled
together as WT/tTA. *P < 0.001 versus WT/tTA (n = 6). (C) Representative TTC-stained heart sections (top) and quantitative analysis of infarct
size (bottom). *P < 0.001 versus WT or tTA (n = 6–7). (D and E) The LV of the WT/tTA and CA-RhoA hearts were fractioned following 30 minutes I/30 minutes R, and cytosolic (cyto) and mitochondrial (mito) cytochrome c (cyto c) were analyzed by Western blots. (D) Representative
blots showing cyto (top) and mito (bottom) cytochrome c level. (RhoGDI and VDAC were used as cytosolic and mitochondrial loading control,
respectively. VDAC was not detected in the cytosol fraction and RhoGDI was not detected in the mitochondrial fraction.) (E) Quantification of
cytochrome c release in the cytosolic fraction. *P < 0.05 (n = 4). Data are shown as mean ± SEM.

reperfusion period. LDH release was 70% lower in CA-RhoA hearts,
demonstrating a cytoprotective effect of RhoA (Figure 3B). Myocardial infarct size following 2-hour reperfusion was likewise markedly
reduced, from 53% ± 3% in WT and 50% ± 3% in tTA, to 20% ± 1%
in CA-RhoA mice (Figure 3C). No protection was seen in doubletransgenic mice maintained on Dox to suppress RhoA expression
(Supplemental Figure 2). CA-RhoA hearts also showed resistance
to mitochondrial damage, as indicated by diminished cytochrome c
accumulation in the cytosolic compartment (Figure 3, D and E).
CA-RhoA hearts show no alteration in activation of AKT, FAK, ERK, PKN,
or expression of iNOS, COX2, and Bcl2 family proteins. To explore the
mechanism for RhoA-mediated protection, we looked for changes
in activation or expression of potential RhoA downstream targets
implicated in cardioprotection. CA-RhoA hearts at 8 weeks off Dox
did not show increases in activated (phosphorylated) AKT, focal
adhesion kinase (FAK), ERK, or PKN (also known as PKC-related
kinase 1 or PRK1) compared with control hearts at baseline (Supplemental Figure 3). There were also no obvious changes in expression of COX2 and iNOS, antiapoptotic Bcl2 and Bcl-xl proteins,
The Journal of Clinical Investigation

or proapoptotic Bax and Bak proteins (Supplemental Figure 3).
Rac1, a member of the Rho small GTPase family that is negatively
regulated by RhoA (17), has been reported to protect against oxidative stress in noncardiomyocytes (18, 19). Activity and expression
of Rac1 were unaltered, however, in CA-RhoA mouse hearts (Supplemental Figure 4). Thus, conventional and previously reported
prosurvival signals were not affected in ways that would provide
cardioprotection in the CA-RhoA mouse heart.
RhoA signaling to novel PKCs and PKD. PKC regulates many cardiac
functions, including cardiomyocyte survival (20). To determine the
activation status of conventional and novel PKC (nPKC) isozymes, we
assessed the membrane and cytosolic localization of 3 representative
PKC isozymes. The most abundant ventricular PKC isozyme, PKCα
(a conventional PKC isozyme), did not show altered membrane localization in CA-RhoA versus control hearts. In contrast, membrane
localization of 2 nPKC isozymes, PKCε and PKCδ, was increased
(and cytosolic localization decreased) in hearts from CA-RhoA
versus control mice (Figure 4A). PKD is an established target for
nPKCs (21, 22), which catalyzes phosphorylation at sites in the acti-
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Figure 4
nPKC isozymes and PKD are
activated in CA-RhoA hearts.
(A) Representative blots and
quantification of cytosolic and
particulate PKCα, PKCδ, and
PKCε fractionated from the
LV of WT, tTA, and CA-RhoA
hearts (8 weeks off Dox).
*P < 0.01 (n = 3–6). (B) PKD
phosphorylation (pPKD) and
expression in LV lysates
from WT, tTA, and CA-RhoA
hearts (8 weeks off Dox).
*P < 0.01 (n = 6). Data are
shown as mean ± SEM.

vation loop of PKD (Ser744/748), leading to its autophosphorylation at the extreme C terminus (Ser916) (21–24). Phosphorylation
of both sites on PKD was markedly increased (by 90% and 81%,
respectively) in CA-RhoA compared with control mice (Figure 4B).
RhoA and PKD are activated during oxidative stress and induce protection
against oxidative stress–induced cell death. To directly demonstrate that
RhoA signaling can activate PKD in cardiomyocytes and to investigate the role of RhoA/PKD in oxidative stress–induced cell death,
we carried out studies using neonatal rat ventricular myocytes
(NRVMs). NRVMs infected with constitutively active (Q63L) RhoA
showed robust increases in PKD phosphorylation (Figure 5A).
Calpeptin, a pharmacological activator of endogenous RhoA, also
increased PKD phosphorylation, and its effect was attenuated by
pretreatment with C3 transferase (Figure 5B). which ribosylates
and functionally inhibits RhoA (25). Both RhoA and PKD were
found to be activated in NRVMs following oxidative stress induced
by H2O2 (Figure 5C). Importantly, we documented a protective role
for these responses based on the observation that treatment with
C3, with a selective PKD inhibitor CID755673 (26), or with PKD
siRNA potentiated H2O2-induced cell death (Figure 5D).
PKD inhibition reverses RhoA-mediated protection against I/R injury
in the heart. We reported previously that I/R activates RhoA in the
isolated perfused mouse heart (5). Here we extended these findings by demonstrating that RhoA activation following I/R is
accompanied by phosphorylation of PKD (Figure 6). The PKD
inhibitor CID755673 effectively decreased PKD phosphorylation
when perfused into control or CA-RhoA hearts for 30 minutes
(Supplemental Figure 5). Accordingly, we used CID755673 pretreatment to determine whether PKD activation serves a protective
role during I/R. Infarct size and LDH release induced by I/R were
both significantly increased in WT/tTA mouse hearts pretreated
with CID755673 (Figure 7, A and B). Moreover, cardioprotection
3272
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against I/R in the CA-RhoA hearts was completely reversed by PKD
inhibition (Figure 7, A and B). These data support the conclusion
that PKD activated during I/R is cardioprotective and that PKD
mediates the robust protective effect of RhoA in I/R injury.
Cardiac-specific RhoA knockout mice (RhoAfl/fl,βMHC-cre) show decreased tolerance to I/R injury. To further support the conclusions reached through
experiments using RhoA gain of function we obtained cardiac-specific RhoA gene–deleted mice (see Methods). Double-transgenic mice
RhoAfl/fl,βMHC-cre showed more than 60% reduction in RhoA expression
in the LV compared with their littermate RhoAfl/fl controls (Figure 8A).
The remaining RhoA protein likely reflects RhoA expression in other
cardiac cell types (e.g., fibroblasts, vascular endothelial cells, and
inflammatory cells) as well as incomplete Cre-mediated excision in cardiomyocytes. PKD expression and phosphorylation in RhoAfl/fl,βMHC-cre
mouse hearts were unchanged at baseline relative to control hearts,
but PKD autophosphorylation following I/R was significantly
attenuated in the hearts in which RhoA was genetically deleted
(Figure 8B). Furthermore, RhoAfl/fl,βMHC-cre mouse hearts showed
significantly increased LDH release and infarct size following I/R
compared with their WT, βMHC-cre, and RhoAfl/fl controls (Figure 8,
C and D). These data indicate that RhoA disruption in cardiomyocytes increases I/R injury and thereby confirm a cardioprotective role
for RhoA and PKD signaling in myocytes during I/R.
Discussion
The small GTPase RhoA plays an important role in transducing
signals from the extracellular matrix and from a subset of G protein–coupled receptors, but its role in regulating cardiac physiology
and pathophysiology has remained elusive. Early studies suggested
that RhoA and its downstream effector ROCK contribute to development of cardiac hypertrophy (9, 10, 27–30). We have observed,
however, that while chronic expression of activated RhoA begin-
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Figure 5
RhoA induces PKD activation in
NRVMs. (A) Adenoviral expression
of RhoA induces PKD phosphorylation. (B) A Rho activator calpeptin
(1 unit/ml, 30 minutes) induces PKD
phosphorylation, which is inhibited by
RhoA inactivation with C3 (2 μg/ml,
18 hours). *P < 0.05 versus calpeptin
(n = 3–4). (C) Time course activation
of RhoA and PKD in response to H2O2
(150 μM) treatment (n = 3–5). (D) Top
panel: PKD knockdown by siRNA (90%
knockdown). Bottom panel: treatment
with C3 (1 μg/ml), CID755673 (50 μM),
or PKD siRNA potentiates cell death
induced by H2O2 (150 μM, 20 hours).
*P < 0.05 versus vehicle H2O2 (n = 4–5).
Data are shown as mean ± SEM.

Further studies examined the mechanism by which RhoA medining in early development can induce hypertrophy (Supplemental
Figure 1) and that a lethal dilated cardiomyopathy and heart failure ates cardioprotection. In the CA-RhoA heart, the autophosphorydevelop with chronic high level expression of RhoA (7), this does lation of PKD was markedly increased, indicative of its activation.
not occur in mice expressing low levels of RhoA in the adult heart. RhoA expression or RhoA activation in NRVMs also increased
The CA-RhoA lines generated and examined in the current study PKD phosphorylation. These data extend previously published
show conditional (upon Dox removal) and modest (2- to 5-fold) work showing that PKD is activated when RhoA is heterologously
increases in active GTP-RhoA, increases comparable to those expressed in COS-7 and HeLa cells (31, 32). There is also increased
induced in the mouse heart by treatment with agonists such as membrane distribution of PKCε and PKCδ in CA-RhoA hearts.
sphingosine-1-phosphate (13) or by I/R (Figure 6). Oxidative stress These nPKC isozymes are known to phosphorylate and activate
or inflammatory mediators released during ischemia and reperfu- PKD (22, 23), and indeed we observed increased phosphorylation
sion would be expected to activate RhoA.Thus, our experimental of established PKC sites on PKD in the CA-RhoA mouse heart.
There is, to our knowledge, no previous evidence that PKD medimodel mimics and allows us to question the role that RhoA serves
when the heart is initially exposed to I/R. Importantly, because ates cardioprotection. Accordingly, we used inhibitors of PKD
RhoA is specifically expressed in cardiomyocytes in CA-RhoA mice to test its role in the cardioprotection observed in the CA-RhoA
and specifically deleted from cardiomyocytes in the
RhoA-knockout mice, we can resolve the effects of RhoA
in cardiomyocytes from its potential effects in other cell
types in the heart. Our data clearly demonstrate that a
modest level of RhoA activation in adult cardiomyocytes
is not pathological but, remarkably, defines a previously
unrecognized pathway for cardioprotection.
When CA-RhoA mouse hearts were challenged by I/R,
we observed profound tolerance to both ex vivo and in
vivo I/R injury. Protection was manifest as 60% to 70%
reductions in infarct size, decreased LDH release, and
markedly improved postischemic contractile performance. Parallel loss-of-function experiments using cardiac-specific RhoA-knockout mice demonstrated markedly Figure 6
RhoA and PKD are activated in response to ex vivo I/R in the heart. Effects of I/R on
increased infarct size and LDH release when cardiomyoRhoA activation and PKD phosphorylation. (A) Representative blots showing time
cytes did not express RhoA. These data provide substan- course of RhoA activation and PKD phosphorylation in response to I/R in the isotial support for the conclusion that endogenous RhoA lated perfused WT mouse hearts. (B) Quantification of change in RhoA activation
is activated in cardiomyocytes during I/R, where it func- and PKD phosphorylation by 30-minute ischemia followed by 30-minute reperfusion.
tions to protect myocytes against I/R injury.
*P < 0.05 versus preischemic control (n = 3 to 4). Data are shown as mean ± SEM.
The Journal of Clinical Investigation
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example, nPKCs, particularly PKCε, mediate cardioprotection (33, 34).
As a downstream target for phosphorylation by the nPKC isozymes
(22, 23), PKD could contribute to their protective effects. The effects
of the Rho-activated kinase, ROCK, in cardiac pathophysiology also
bear comment, since several laboratories have reported salutary
effects of inhibiting or deleting ROCK, suggesting that Rho activation in the heart is deleterious (5, 30, 35). In this regard, a key element of the data presented here is that our models have allowed us
to focus on what RhoA does in the cardiomyocyte, distinct from the
potential ROCK-mediated functions of RhoA in fibroblasts (30, 36),
arterial smooth muscle cells (37–39), or endothelial cells (40, 41),
where proliferation or membrane permeability changes would be
maladaptive. The unexpected cardioprotective role of RhoA in cardiomyocytes, taken with evidence that it is activated at early times
following reperfusion, suggests that RhoA is not always a villain and
that one may want to facilitate rather than block its activation at
early times during reperfusion of the ischemic heart.
In conclusion, our studies demonstrate that modest levels of
RhoA activation in adult mouse cardiomyocytes provide striking
protection against I/R injury and that genetic deletion of RhoA in
cardiomyocytes renders the heart more susceptible to I/R damage.
Our findings reveal a previously undescribed signaling pathway for
RhoA in the heart and suggest that PKD mediates cardioprotection.
These new insights into the effects of RhoA in I/R injury suggest
that interventions that activate RhoA could play an important physiological or therapeutic role in promoting cardiomyocyte survival.
Methods

Figure 7
PKD inhibition enhances I/R injury and reverses cardioprotection in
the CA-RhoA heart. WT, tTA, and CA-RhoA hearts were perfused with
PKD inhibitor CID755673 (50 μM) or DMSO for 30 minutes before
I/R. (A) LDH release to the coronary effluent following 45-minute
reperfusion. *P < 0.005 versus DMSO (n = 5–9). (B) Representative
TTC-stained ventricular sections (top); quantitative analysis of infarct
size (bottom). *P < 0.005 versus DMSO (n = 5–9). Sham, WT/tTA
mouse hearts subjected to perfusion without ischemia with DMSO or
CID755673. Data are shown as mean ± SEM.

mouse heart. Either of 2 classes of PKD inhibitor significantly
reversed cardioprotection against I/R injury (Figure 7 and Supplemental Figure 7). We further demonstrate that both RhoA and
PKD are activated in response to oxidative stress induced by I/R in
the WT mouse heart and that I/R injury in the WT mouse heart is
exacerbated by inhibition of PKD. Finally, we provide evidence that
the PKD activation that occurs with I/R is prevented when RhoA is
genetically deleted from cardiomyocytes, and this is accompanied
by increased infarct size and LDH release. Studies using NRVMs
additionally show that H2O2 activates RhoA and PKD and that
acute loss of function of RhoA or PKD by siRNA or pharmacological inhibitors increases H2O2-induced DNA fragmentation. Taken
together, these data implicate RhoA and PKD in a previously unexplored protective signaling pathway to counteract the deleterious
effects of oxidative stress on cardiomyocytes.
It is of note that RhoA and PKD, identified here as what we believe
to be novel players in cardioprotection, could be involved in the pathways utilized by more established cardioprotective mediators. For
3274
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An expanded methods section is available in the Supplemental Materials
and Methods. All procedures were performed in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee of UCSD.
Generation of cardiac-specific inducible RhoA transgenic (CA-RhoA) mice. Transgenic mice were generated in the Dorn laboratory using the tet-off system
developed by the Robbins laboratory (16). For the responder mouse line,
HA-tagged human constitutively activated RhoA (a gift from G. Bokoch,
The Scripps Research Institute, La Jolla, California, USA) was cloned
into a modified αMHC promoter construct that allows tetracycline/Dox
responsive expression (Dox-off) in the heart when crossed with the driver
transgenic mouse line carrying the αMHC-driven tTA. Both the responder
(modified α-MHC–RhoA) line and the driver line (αMHC-tTA) are in the
FVB/N background. Dox was administered in the food until 3 weeks after
birth to inhibit transgenic RhoA expression and to eliminate developmental effects of RhoA. Dox was removed after 3 weeks of age to induce cardiac-specific expression of transgenic RhoA.
RhoA activation assay. RhoA activation was determined by affinity pulldown assay using a glutathione S-transferase (GST) fusion protein of the
RhoA binding domain of the RhoA effector rhotekin, as described previously
by our group (42). Freshly isolated LVs were rinsed with ice-cold Tris-buffered saline, lysed in buffer containing 50 mM Tris, pH 7.4, 0.1% Triton X-100,
150 mM, NaCl, 5 mM MgCl2, and 10% glycerol, supplemented with protease
and phosphatase inhibitors, clarified by brief centrifugation, and then incubated with the sepharose-bound GST-rhotekin-RhoA binding domain for
45 minutes at 4°C. The beads and precipitated proteins were washed, boiled,
and separated by SDS-PAGE. The precipitated GTP-bound RhoA was normalized to total RhoA present in the whole cell (or tissue) lysate.
Histological analysis. Tissues were fixed in 4% paraformaldehyde/PBS,
dehydrated in 70% ethanol, embedded in paraffin wax, and sectioned.
Paraffin sections were stained with H&E or Tri. To determine the size of
cardiomyocytes, transverse paraffin sections were labeled with tetramethyl
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Figure 8
Cardiac-specific RhoA knockout enhances I/R injury in the heart. (A) Representative blots showing RhoA expression in RhoAfl/fl and RhoAfl/fl,βMHC-cre
hearts. (B) Representative blots and quantification showing PKD autophosphorylation in RhoAfl/fl and RhoAfl/fl, βMHC-cre hearts following I/R. *P < 0.05
(n = 3–4). (C and D) WT, βMHC-cre, RhoAfl/fl, and RhoAfl/fl,βMHC-cre hearts were subjected to global I/R. (C) LDH release to the coronary effluent
following 45-minute reperfusion. *P < 0.05 versus controls (n = 4–5). (D) Representative TTC-stained ventricular sections (top); quantitative
analysis of infarct size (bottom). *P < 0.05 (n = 4–7). Data are shown as mean ± SEM.

rhodamine isothiocyanate–labeled (TRITC-labeled) wheat germ agglutinin (WGA) (Sigma-Aldrich), nuclei were counterstained with DAPI (Vector
Laboratories), and the cross-sectional area of myocytes in the LV wall was
determined using Image Pro Plus software as described previously (7).
In vivo I/R. Coronary occlusion/reperfusion was performed as described
in detail in previous studies (43). Age-matched male mice were anesthetized by intraperitoneal injection of pentobarbital sodium (60 mg/kg),
intubated, and ventilated with 65% oxygen during the surgery. LAD was
occluded at a position 2 mm from the tip of the left auricle. Myocardial
ischemia was verified by blanching of the LV and by changes in electrocardiogram. Following 1-hour LAD occlusion and 24-hour reperfusion, the
LAD was reoccluded and 5% Evans blue dye (0.2 ml) was injected into the
LV cavity to define the nonischemic zone. The ventricles were frozen and
cut transversely into 5 slices of equal thickness followed by incubation in
1% triphenyltetrazolium chloride (TTC)/PBS at 37°C for 8 minutes and
then were fixed in 10% formalin-PBS for 24 hours. Fixed slices were then
scanned, and ImageJ software (NIH) was used to measure and calculate the
AAR, infarct tissue, and the total area.
Isolated perfused (ex vivo) I/R. Hearts from age-matched male mice were
removed quickly and perfused in a retrograde manner with modified KrebsHenseleit buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 25 mM
The Journal of Clinical Investigation

NaHCO3, 0.5 mM EDTA, 1.2 mM MgSO4, 11 mM glucose, 1.5 mM NaPyruvate, and 2 mM CaCl2) in a Langendorff apparatus at constant pressure (80 mmHg). To record cardiac contractile function, a water-filled balloon made of plastic film connected to a pressure transducer was inserted
into the LV. After stabilization, hearts were subjected to 30 minutes of
global ischemia, followed by 60 minutes of reperfusion. The LVDP (peak
systolic pressure minus LV end diastolic pressure [LVEDP]), +dP/dt, and
−dP/dt were monitored and recorded. To measure infarct size, hearts were
subjected to 45-minute global ischemia and 2-hour reperfusion; the ventricles were then frozen and cut transversely into 5 slices of equal thickness.
For the cardiac-specific RhoA knockout (RhoAfl/fl,βMHC-cre) mice and their
control mice, the ischemia time was adjusted to 25 minutes. The slices
were then incubated in 1% TTC/PBS and fixed in 10% formalin-PBSe for
24 hours. Fixed slices were then scanned, and ImageJ was used to measure
and calculate the size of the infarct area and the total area.
LDH activity assay. To measure LDH release during reperfusion, hearts
were subjected to 45-minute global ischemia and 2-hour reperfusion in the
Langendorff mode. Coronary outflow was collected during the last 10 minutes of baseline perfusion and the first 45-minute reperfusion following
ischemia; the volume was measured and the cumulated LDH release was
determined using an LDH activity assay kit (MBL International Corp.).
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Generation of cardiac-specific RhoA-knockout (RhoAfl/fl,βMHC-cre) mice. The cardiac-specific RhoA knockout mice were generated in the Molkentin laboratory using the RhoA loxP-targeted (fl) mice generated in Yi Zheng’s laboratory,
in which exon 3 was flanked by loxP sites to allow tissue-specific deletion,
as described in Supplemental Figure 6. Mice expressing Cre recombinase
under control of the endogenous βMHC promoter were described previously (44). Mice harboring the RhoAfl/fl alleles and βMHC-cre transgenic mice,
independently generated from the same back-cross (C57BL/6 – SV129),
were crossed to generate RhoAfl/fl,βMHC-cre mice in the Molkentin laboratory.
Statistics. All results are reported as mean ± SEM. Comparison of 2 groups
was accomplished using an unpaired Student’s t test. Data from experiments with more than 2 groups were compared by 1-way ANOVA followed
by the Tukey post hoc test for comparison between groups. P < 0.05 was
considered to be statistically significant.
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